- Trial phase
- Phase 3
- Time to market
- If the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.
- Why 5/10
- The next hard catalyst is the pivotal Phase 3 HARMONY topline data readout, guided for the second half of 2027 (roughly 8-14 months from today). Pegtibatinase is a major pipeline asset but Travere also has the approved commercial product FILSPARI generating significant revenue, so the stock is not a pure single-asset binary. No PDUFA date exists.
The next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.
Price Chart
Executive Summary
Pegtibatinase (TVT-058) is Travere Therapeutics' investigational enzyme replacement therapy for classical homocystinuria (HCU), a rare genetic metabolic disorder with no approved disease-modifying treatment. Phase 1/2 data showed a promising 67% reduction in homocysteine levels, and the drug holds FDA Breakthrough Therapy and Orphan Drug designations. However, the pivotal Phase 3 HARMONY study was paused for over a year due to manufacturing scale-up issues before restarting in early 2026, and topline data is not expected until the second half of 2027. Travere now has a commercially successful approved drug (FILSPARI for kidney diseases) that generated roughly $200M in Q3 2026, reducing dependence on pegtibatinase but also making the pipeline asset less of a pure binary for the stock.
How It Works
Pegtibatinase is an enzyme replacement therapy designed to replace a missing or faulty enzyme (cystathionine beta-synthase, CBS) in patients with classical homocystinuria (HCU), a rare genetic disorder. By supplying a working version of the enzyme, it aims to break down toxic levels of homocysteine that build up in the blood and cause life-threatening blood clots, vision problems, and other complications. The drug is given as a subcutaneous injection.
Trial Status
The pivotal global Phase 3 HARMONY study (NCT06247085) resumed enrollment in Q1 2026 after a voluntary pause from September 2024 due to commercial manufacturing scale-up improvements. The study targets ~70 patients aged 12-65 with total homocysteine levels >= 50 micromol/L despite standard of care. Topline data is expected in the second half of 2027. The prior Phase 1/2 COMPOSE study (NCT03406611) is active but no longer recruiting, having demonstrated a 67.1% mean relative reduction in homocysteine at the highest dose.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 HARMONY topline efficacy/safety data readout expected 2H 2027
- Quarterly earnings updates providing enrollment progress on HARMONY study
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Travere Therapeutics, Inc. 8-K TVTX ·Originating report